AgomAb Therapeutics NV

AGMB · NASDAQ

AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.

Follow Add to Watchlist Ask Question

NASDAQ AGMB Coverage Bootstrap Healthcare Biotechnology Fibrosis

Latest ReportMay 14, 2026AGMB: the IPO biotech with two fibrosis readouts before its runway clock mattersView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.